Figure 3 indicates that the percentage of tumor-distant tissues showing methylation status of RASSF1A, MGMT or DAPK1 promoters ≥ LOQ was lower (6 %) than the percentage of tumor-adjacent tissues (29 % (5/17), 19 % (3/16) and 13 % (2/16), respectively), which, in turn, was lower than the percentage of tumor tissues (59 % (10/17), 41 % (7/17) and 38 % (6/16), respectively). This evidence concerns the gene MGMT and neoplasm.